S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells. Combining rituximab with chemotherapy may kill more cancer cells.
PURPOSE: Phase II pilot study to study the effectiveness of combining chemotherapy with
rituximab in treating patients who have newly diagnosed mantle cell lymphoma.